The DNA and gene cloning services market is anticipated to grow at a CAGR of over 15% In order to avail benefits, such as technical competence, reduced cost, and fast delivery of high-quality DNA and gene customized clones, several players have demonstrated a preference to leverage expertise of DNA and gene cloning service providers. London Roots Analysis has announced the addition of “DNA and Gene Cloning Market , 2022-2035” report to its list of offerings. DNA and gene cloning have diverse applications, including modern biotechnological, medicinal, and several diagnostic ones as DNA and gene cloning has proven to be beneficial for research and development in the biopharmaceutical and healthcare industries. Presently, a number of players having dedicated facilities, cutting-edge machinery, and production lines, are offering DNA and gene cloning services to the various stakeholders in this domain. In 1973, a group of scientists reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments. Over time, gene and DNA cloning has proved to be an important tool for researchers in their studies focused on genetics. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market/request-sample.html Key Market Insights Around 80 companies claim to offer DNA and gene cloning services, globally Majority (59%) of the stakeholders are headquartered in North America, followed by those based in Europe (22%), and Asia-Pacific (19%). Further, this segment of the industry is dominated by the presence of small players (11-50 employees), representing 35% of the total service providers. Close to 32% players claim to act as one-stop-shops, offering services for gene synthesis, custom cloning, and sub-cloning Close to 80% of the DNA and gene cloning service providers offer custom cloning, followed by companies offering gene synthesis (68%), sub-cloning (50%), and other services, such as RNA cloning and vector cloning (31%). It is worth mentioning that most of the service providers (61%) offer restriction enzyme-based cloning. Over 1,350 patents related to DNA and gene cloning in biopharmaceutical industry have been filed / granted since 2017 Owing to the increase in research and development efforts by various industry and non-industry players engaged in this domain, close to 60% of patent applications have been filed post-2018. It is worth noting that 57% patents related to DNA and gene cloning have been filed by non-industry players. Close to 6,900 articles related to DNA and gene cloning, have been published in reputed scientific journals since 2018 More than 45% of the articles focused on DNA and gene cloning were published post-2019. Popular journals that have published multiple articles include Methods in Molecular Biology, International Journal of Biological Macromolecules, Developmental and Comparative Immunology, Protein Expression and Purification, and International Journal of Molecular Sciences. Over 35 global events related to DNA and gene cloning have been organized since 2017 Majority of the events related to DNA and gene cloning were organized in Asia-Pacific (64%). It is worth highlighting that the agendas of the events organized post-2020 include discussions on the potential, advancements and challenges associated with DNA and gene cloning techniques. For additional details, please visit https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The human microbiome market is anticipated to grow at a CAGR of 24% till 2035 With the increasing concept of precision medicine, several scientists have demonstrated interest in the therapeutic manipulation of human microbiome (commonly gut bacteria) for the treatment of a wide range of disease indications. Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings. The microbiome-based therapies pipeline features six drugs in phase III clinical development, over 200 candidates in other clinical and preclinical stages of development along with more than 60 diagnostics and screening / profiling tests that are commercialized for the detection of various diseases. However, the current microbiome market is driven by the fecal microbiota therapies approved by the FDA, particularly for the recurrent CDI and the commercialized diagnostic tests available to the patients. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/281/request-sample.html Key Market Insights Over 230 drug candidates are currently being developed by more than 70 drug developers Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders. FMTs are the only commercially available microbiome therapies approved by the FDA These therapies are primarily used for the treatment of recurrent Clostridium difficile infection (rCDIs). It is worth mentioning that more than 400 trials have been registered for evaluating these therapies for a wide range of indications. Partnership activity in this domain has increased at a CAGR of 26%, between 2017 and 2021 Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period. More than USD 1 billion has been invested by both private and public investors, since 2017 Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million. Outsourcing has become an integral part of the microbiome and live biotherapeutics development process Presently, over 25 service providers claim to offer a multitude of contract manufacturing services for microbiome and live biotherapeutic products. It is worth noting that close to 10 firms were established post 2010 and around 45% of the players are located in Europe. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

Oral Proteins and Peptides Market Over the years, advances in recombinant DNA technology and ex vivo synthesis of biomolecules have led to the development and (in some cases) approval of several protein / peptide-based therapeutics. Considering the therapeutic advantages associated with proteins and peptides, this field has witnessed significant activity; researchers are actively evaluating orally bioavailable interventions. However, owing to their inherently complex structure and comparatively low stability (in in vivo conditions), proteins / peptides are predominantly administered parenterally. Recent strides in drug delivery solutions have enabled scientists to successfully explore and exploit alternative routes of drug delivery, such as transdermal, intranasal, pulmonary and oral, for protein / peptide-based therapeutics. Of these, the oral route of delivery is considered to be the most patient-friendly. This has led several companies to invest in the development of orally administered biologics. The delivery of proteins and peptides utilizes the following routes of administration. Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/192/request-sample.html Although studies have reported that over XX oral drug delivery technologies have been designed so far, our research indicates that only XX% of the aforementioned technologies are currently being used to develop therapeutic proteins / peptides. Owing to the numerous advantages of oral drug delivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral proteins / peptide therapeutics market is anticipated to witness significant growth in the coming future. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/oral-proteins-and-peptides-market/192.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035 An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries. Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings. Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/needlestick-safety-market/request-sample.html Key Market Insights Currently, around 120 needlestick safety injection devices are available in the market More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections. Over 50 companies claim to develop needlestick safety injection devices, worldwide Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%). Partnership activity within this field has grown significantly between 2020 and 2022 Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions. Over USD 260 million has been invested by both private and public investors, since 2016 Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain. Close to 20 global events were organized in the past couple of years in this industry Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries. More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018 Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes. For additional details, please visit https://www.rootsanalysis.com/reports/needlestick-safety-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The cell invasion and migration assays market is projected to grow at a CAGR of 8% In recent years, the potential of cell invasion and migration assays with respect to discovery, diagnosis and screening of diseases has been widely recognized, which has further presented lucrative opportunities for players offering such products. London Roots Analysis has announced the addition of the “Cell Invasion and Migration Assays Market, 2022–2035” report to its list of offerings. Owing to several advantages offered by cell invasion and migration assays in analyzing and quantifying cellular mechanisms, industry stakeholders have undertaken numerous R&D initiatives focused on exploiting the use of such assays to expediate discovery timelines and optimize the total development cost. Considering the various advantages offered by these cell-based assays, researchers across the globe have undertaken several initiatives to use these platforms for the diagnosis of a myriad of disease indications. The advancements in various technologies have propelled life science companies to use these assays in the drug discovery process, to enable the identification of potential lead candidates. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market/request-sample.html Key Market Insights Presently, more than 80% of the total assay providers are based in North America This segment of the industry is dominated by the presence of companies that were established pre-2000 (64%), followed by firms established during 2000-2010 (27%). In addition, most of the players engaged in this domain are small firms (less than 100 employees), representing over 45% of the total assay providers. Currently, over 80 cell invasion and migration assays are available in the market It is worth noting that most of the cell invasion and migration assays are currently being used for tumor studies (89%), followed by those employed for screening purposes (79%). Further, most of the assays are being developed for adherent cell cultures (48%), followed by those being manufactured for both adherent and suspension cell cultures (40%). 55% players claim to be capable of offering both cell invasion as well as cell migration assays 64% of the cell invasion and migration assays can be stored under frozen temperature (-18°C to -40°C), followed by those stored under refrigerated conditions (+1°C to +18°C) (36%). Further, it is worth noting that most of the cell invasion and migration assays are being used to conduct 100 tests (37%). This was followed by assays being developed to conduct 12 (35%) and 96 tests (23%). Over 650 articles focused on cell invasion and migration assays have been published, since 2021 Majority of the scientific literature published in this domain was focused on research (96%), followed by review articles (4%). It is worth mentioning that articles related to cell invasion and migration assays have been affiliated by over 300 universities. Patents filed / granted for cell invasion and migration assays have increased at a CAGR of more than 45%, since 2017 Of the total, around 55% of the patents were applications, followed by those that have been granted approval (45%). Around 63% of these intellectual property documents were filed / granted in North America; with the maximum number of patents having been filed in the US, since 2017. For additional details, please visit https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market.html You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The RNA sequencing services market is anticipated to grow at a CAGR of ~8% by 2035 In order to avail benefits, such as technical competence in sequencing large-sized genes, reduced cost, and fast delivery of high-quality data, researchers and industry players have demonstrated a preference to outsource RNA sequencing. London Roots Analysis has announced the addition of “RNA Sequencing Services Market, 2022-2035” report to its list of offerings. Despite the various technological advancements in RNA sequencing, there are several existing challenges, including difficulty in the sequencing of large-sized genes, shortage of human resources, lack of tools for data manipulation and analysis, and high capital requirement. In order to overcome these challenges and obtain a high-quality output, the outsourcing of RNA sequencing is considered as a preferable option, among other alternatives, by the companies engaged in RNA sequencing. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/rna-sequencing-services-market/request-sample.html Key Market Insights Currently, more than 70 companies claim to offer RNA sequencing services, globally Nearly 70% of the RNA sequencing service providers have been established post 2000, most of these are located in North America (58%) followed by Europe (22%). Further this segment of the industry is dominated by presence of mid-sized players (51-1,000 employees), representing 44% of the total service providers. Nearly 75% of the companies employ Illumina’s sequencing platform Of these, nearly 20% players offer services related to small RNA sequencing, followed by those offering services for mRNA sequencing (19%). Further, more than 80% of players claim to offer turnaround time of less than two weeks for different types of RNA sequencing services. Close to 1,050 grants have been awarded to support the research initiatives focused on RNA sequencing, since 2018 Grants worth USD 487 million have been awarded to various companies / organizations working in this domain. Close to 85% of the grants have been awarded for less than five years, out of which 15% grants were funded by the National Cancer Institute. Over 340 patents related to RNA sequencing have been filed / granted, since 2018 Owing to the increase in research and development efforts by various industry and non-industry players engaged in this domain, close to 87% of patent applications have been filed post-2018. It is worth noting that 58% patents related to RNA sequencing were filed / granted in Asia Pacific, alone. Presently, more than 85 NGS library preparation kits are available in market for RNA sequencing Majority (75%) of the kits offer turnaround time of less than five hours, out of which 80% kits contain enzyme mix as components. Further, most of the kits (40%) use plasma as the starting material, followed by kits that use serum (34%) and saliva (8%) as input samples. North America and Europe are anticipated to capture larger share (~70%) of the market by 2035 The market will be primarily driven by RNA sequencing for research purposes (93%). Further, clinics and hospitals are expected to occupy larger share (45%) of the overall market (in terms of service-based revenues), by 2035. For additional details, please visit https://www.rootsanalysis.com/reports/rna-sequencing-services-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The adeno-associated viral vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections. London Roots Analysis has announced the addition of “Adeno Viral Vector Market, 2022-2035” report to its list of offerings. Owing to their unique biology, simple structure and lack of disease correlation, the adeno-associated viral vectors have garnered significant interest within the medical community. In fact, various adeno-associated viral vector-based therapies have been developed for the treatment of multiple indications, including retinitis pigmentosa, cystic fibrosis and Duchenne muscular dystrophy. As a result, the demand for such vectors have increased tremendously, thereby creating lucrative opportunities for the players engaged in the adeno-associated viral vector market. Among various gene delivery vectors available, adeno-associated viral (AAV) vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors based drugs, LUXTURNA® and ZOLGENSMA®. Considering the prevalent trends and projected opportunity associated with the overall adeno-associated viral vectors / AAV vector domain, we believe that the market is anticipated to witness substantial growth in the foreseen future. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/adeno-associated-viral-vector-market/request-sample.html Key Market Insights More than 550 adeno-associated viral vector-based therapies have been / are being evaluated across different stages of development for the treatment of various disorders Close to 20% of the pipeline candidates are under clinical evaluation; majority (26%) of these candidates are being developed for the treatment of neurological disorders, followed by those being evaluated for the treatment of ophthalmic disorders (21%). More than 155 clinical trials have been registered for the evaluation of adeno-associated viral vector-based therapies, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 20%, since 2010. Of the total number of trials registered, close to 25% have already been completed, while 46% of the studies are actively recruiting participants. More than 50 start-ups have emerged in the last 10 years in the adeno-associated viral vector domain Close to 60% of the start-ups have been established in North America. Among these, more than 95% of the firms are based in the US. This is followed by Europe, accounting for more than 30% of the start-ups focused on adeno-associated viral vectors. North America is anticipated to capture larger share of the adeno-associated viral vector market by 2035 The market will be primarily driven by the manufacturers developing therapies for the treatment of oncological disorders (20%). In addition, by 2035, majority market share of the adeno-associated viral vector-based therapies is anticipated to be dominated by commercial scale of operation (46%), followed by preclinical (40%) and clinical (14%). For additional details please visit https://www.rootsanalysis.com/reports/adeno-associated-viral-vector-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

VIRAL VACCINE CELL CULTURE MEDIA: OVERALL MARKET LANDSCAPE Innovation is considered to be one of the key drivers of the pharmaceutical industry. Over the past few decades, various technological advances and a few fortuitous discoveries have significantly changed the practice of medicine. One such advancement that came into light was the development of vaccines, which have demonstrated significant therapeutic potential. Over time, vaccine research has evolved significantly, which is now being driven by several innovative technologies, including those involving the use of recombinant deoxyribonucleic acid (DNA) and nucleic acids. Further, with the discovery of more disease targets, players engaged in vaccine development have shifted their focus towards the development of vaccines that target a myriad of disease indications other than infectious diseases. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. A vaccine is a biological substance that is used to stimulate the host’s immune system against a specific disease. It is worth highlighting those vaccines are also referred to as immunizers, due to their ability to take advantage of the host’s natural immune system to prevent illnesses. Generally, the vaccines contain a weakened or an inactivated (killed) form of a virus / a small (in virulent) part of the virus, which is called the antigen. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market/request-sample.html Viral vaccines were first produced in the early 1940s, using embryonated chicken eggs to replicate a broad variety of viruses. Over 30 human vaccines, manufactured using this technique, have been licensed; however, the production capacity associated with this method was limited due to the unavailability of fertilized eggs. Further, in 1950s, an alternative technology based on animal cell culture, which used primary cells as substrate, was developed. Then, in the late 1960s, continuous cell lines were recognized as suitable hosts for human vaccine production, however, the first production process using this technique was established in 1977. One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Cell cultures can be broadly classified into two categories, namely adherent and suspension cell cultures.  Adherent Cell Culture: As the name suggests, these cells must be attached to a surface to grow. These cells can be cultured in flasks, roller bottles and other cell culture vessels capable of handling anchorage-dependent cell types.  Suspension Cell Culture: In this process, cells or cluster of cells are allowed to function and multiply in an agitated growth medium. Suspension cells can be cultured in small-scale vessels, such as spinner flasks or large-scale vessels (single-use bioreactors). These cells offer a vast range of scalability, thereby, making it a preferred option for manufacturers in order to increase their operational efficacy. For additional details, please visit link https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The novel cardiovascular drug delivery devices market is projected to grow at a CAGR of 9.3% Given the growing number of patients suffering from cardiovascular disorders and the high associated financial burden, cardiovascular drug eluting stents have emerged as a safe and efficient novel drug delivery device to assist in providing effectual treatment. Roots Analysis has announced the addition of “Novel Cardiovascular Drug Delivery Devices Market, 2022-2035” report to its list of offerings. In order to prevent the critical effects of vessel narrowing and plaque buildup in arteries, various coronary interventional devices are being used; cardiovascular stents have emerged as one of the most preferred solutions to mitigate the aforementioned concerns. Traditionally, bare-metal stents were used extensively to open the blocked passages and restore adequate blood flow to the heart. However, in recent years, a shift in preference has been observed towards the use of drug-eluting stents, which are coated with a polymer carrying an antiproliferative drug. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/novel-cardiovascular-drug-delivery-devices-market/request-sample.html Key Market Insights Over 90 cardiovascular drug eluting stents are presently available in this market space About 65% of these devices are coated with sirolimus drug, followed by those coated with everolimus and paclitaxel. Further, more than 70% of the stents are manufactured by using cobalt alloy. It is interesting to mention that stent length of more than 85% of the devices is in the range of 31 mm to 50 mm. ~40 players are currently be engaged in the production of cardiovascular drug eluting stents Majority of the players engaged in this domain are large firms (501-10,000 employees, 41%), followed by mid-sized players (51-500 employees, 26%), very large players (10,000+ employees, 18%) and small (2-50 employees, 15%) companies. Additionally, most of the service providers (38%) are based in Asia, followed by those having headquarters in Europe and North America. Over 70 novel therapeutics are being developed to target a wide range of cardiovascular diseases Majority (50%) of the therapies targeting cardiovascular disorder are currently in early stages of development (discovery and preclinical). It is also worth mentioning that over 65% of the drug candidates targeting cardiovascular diseases are gene therapies. More than 50 players are engaged in offering novel cardiovascular-based services / solutions Over 60% of the players offering such services / solutions are based in North America. It is interesting to mention that this domain is dominated (more than 40%) by the players offering digital therapeutics services. Till date, 900+ patents have been filed related to novel cardiovascular drug delivery devices In terms of the intellectual property developed across the world, the R&D activity is currently concentrated in North America and Europe. Further, most patented inventions are focused on the development of bioresorbable and biodegradable drug eluting stents. Global demand for novel cardiovascular drug delivery devices is anticipated to grow at a CAGR of over 13%, during 2022-2035 In 2035, sirolimus eluting stents are expected to contribute over 50% of the total demand for novel cardiovascular drug delivery devices, majority (~70%) of such devices are manufactured using cobalt chromium as a stent material. For additional details, please visit https://www.rootsanalysis.com/reports/novel-cardiovascular-drug-delivery-devices-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035 An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries. Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings. Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/needlestick-safety-market/request-sample.html Key Market Insights Currently, around 120 needlestick safety injection devices are available in the market More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections. Over 50 companies claim to develop needlestick safety injection devices, worldwide Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%). Partnership activity within this field has grown significantly between 2020 and 2022 Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions. Over USD 260 million has been invested by both private and public investors, since 2016 Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain. Close to 20 global events were organized in the past couple of years in this industry Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries. More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018 Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes. North America and Europe are anticipated to capture more than 75% of the market by 2035 Growth in this domain is anticipated to be primarily driven by the rising cases of needlestick injuries amongst the healthcare workers. The Asia-Pacific needlestick safety injection devices market currently accounts for more than 20% of the global market. For additional details, please visit https://www.rootsanalysis.com/reports/needlestick-safety-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/